Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 Glomerulopathy
Phase 2, Multicenter, Randomized, Open-label, Controlled, 2-arm Cross-over Study to Evaluate the Clinical Efficacy of a Renin Inhibitor, Aliskiren, Compared to an Angiotensin Converting Enzyme Inhibitor, Enalapril, in C3 Glomerulopathy
Sponsor: Region Skane
This PHASE2 trial investigates C3 Glomerulonephritis and C3 Glomerulopathy and is currently actively recruiting participants. Region Skane leads this study, which shows 9 recorded versions since 2020 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
9 versions recorded-
Jul 2025 — Present [monthly]
Recruiting PHASE2
-
Sep 2024 — Jul 2025 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Apr 2023 — Jul 2024 [monthly]
Recruiting PHASE2
-
Feb 2022 — Apr 2023 [monthly]
Recruiting PHASE2
▶ Show 4 earlier versions
-
Jan 2021 — Feb 2022 [monthly]
Recruiting PHASE2
-
Nov 2020 — Jan 2021 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Apr 2020 — Nov 2020 [monthly]
Not Yet Recruiting PHASE2
-
Jan 2020 — Apr 2020 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Region Skane
For direct contact, visit the study record on ClinicalTrials.gov .